Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical study evaluating the investigational combination of islatravir and lenacapavir.

The data was presented at the ID Week 2024.

At 48 weeks, the investigational combination maintained a high rate (n=49; 94.2%) of viral suppression (HIV-1 RNA <50 copies/mL) in virologically suppressed adults, a secondary endpoint of the study.

Also Read: Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments.

Zero participants had a viral load of ≥50 copies/mL at Week 48.

In this open-label, active-controlled study, virologically suppressed adults (n=104) on ...